Biogen’s Aduhelm Sales Total $2 Million in Second Quarter

The drug maker Biogen reported on Thursday that its controversial Alzheimer’s drug Aduhelm introduced in $2 million in its first few weeks of availability, the primary income for a therapy that’s anticipated to generate billions of {dollars} and pressure Medicare’s price range inside just a few years.

The corporate didn’t disclose the variety of sufferers which have acquired the drug, which is priced at $56,000 yearly on common. Biogen’s chief government, Michel Vounatsos, mentioned on an earnings name {that a} “large chunk” of the income had come from stockpiled stock and that the drug’s launch has been considerably slower than the corporate had anticipated.

A number of trade analysts estimated primarily based on the income determine that fewer than 100 sufferers had been handled to date. The drug had been anticipated to get off to a modest begin. Many insurers haven’t but determined the right way to cowl it. Administration websites — usually reminiscence clinics that see sufferers with cognitive issues — have been slowed by the complexities of administering the drug, which should be given as a month-to-month intravenous infusion.

The federal company that administers Medicare introduced earlier this month that it will provoke a monthslong assessment to find out whether or not to standardize protection of the drug throughout the nation, a step that would prohibit which sufferers obtain it. Within the meantime, some Medicare Benefit plans, a substitute for conventional Medicare that’s provided by personal insurance coverage corporations, have already permitted sufferers to obtain the drug, the corporate mentioned.

Biogen executives spent a lot of the earnings name on Thursday defending Aduhelm and the method that led to its approval.

The drug’s approval final month generated intense scrutiny, largely as a result of there may be scant proof that it may assist sufferers. Some main medical facilities have determined to not provide it, and two congressional committees are investigating the drug’s approval and its worth. Critics have additionally questioned the shut collaboration between Biogen and the Meals and Drug Administration within the lead-up to the approval.

Show More

Related Articles

Back to top button